15 completed, 5 unknown, 3 active not recruiting, 1 recruiting. 25 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 25 | Completed 15, Unknown 5, Active not recruiting 3, Recruiting 1, Terminated 1 |
Follow Recurrent Cervical Carcinoma: new trials by email Literature Review of Recurrent Cervical Carcinoma trials Research Report on Recurrent Cervical Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| PRGN-2009 in Combination With Pembrolizumab in Patients With Recurrent or Metastatic Cervical Cancer PRGN-2009 plus Pembrolizumab - Cervical Cancer, HPV-Related Carcinoma | Phase 2 | Recruiting | Precigen, Inc | 24 | 2025-11-11 | 2026-04-23 |
| Dostarlimab and Cobolimab in Advanced Cervical Cancer Dostarlimab, Cobolimab - Cervical Cancer, Advanced Cervical Carcinoma | Phase 2 | Active not recruiting | Meghan Shea | 66 | 2024-03-11 | 2026-01-13 |
| Tislelizumab and Radiotherapy for Recurrent Cervical Cancer Tislelizumab plus radiotherapy - Recurrent Cervical Carcinoma, Metastatic Cervical Carcinoma | Phase 2 | Unknown | Lei Li | 58 | 2022-03-27 | 2022-04-11 |
| Donafenib for Recurrent Cervical Cancer Donafenib combined with paclitaxel and platinum ± PD-1 antibody - Targeted Therapy, Chemotherapy | Phase 2 | Unknown | Lei Li | 20 | 2022-03-27 | 2022-04-04 |
| Immunotherapy for Recurrent Cervical Cancer Refractory to Platinum-based Chemotherapy: Multi-Center Trial Anti-PD-1 antibody camrelizumab, Albumin-bound paclitaxel - Recurrent Cervical Carcinoma, Persistent Advanced Cervical Carcinoma | Phase 2 | Unknown | Lei Li | 122 | 2022-03-13 | 2022-03-22 |
| Combination of Nimotuzumab and Radiotherapy for Recurrent Uterine Cervical Squamous Carcinoma Combination of nimotuzumab and radiotherapy - Recurrent Cervical Carcinoma, Radiotherapy | Phase 2 | Unknown | Lei Li | 43 | 2020-12-19 | 2020-12-22 |
| Camrelizumab Combined With Chemotherapy for Recurrent or Advanced Cervical Neuroendocrine Carcinomas Drug therapy - Chemotherapy, Anti-pd-1 Antibody | Phase 2 | Unknown | Lei Li | 20 | 2020-11-15 | 2020-11-19 |
| Immunotherapy for Recurrent Cervical Cancer Refractory to Platinum-based Chemotherapy A combination of anti-PD-1 antibody camrelizumab and albumin-bound paclitaxel - Recurrent Cervical Carcinoma, Persistent Advanced Cervical Carcinoma | Phase 2 | Completed | Lei Li | 34 | 2019-12-06 | 2022-03-15 |
| First-line Chemotherapy for Recurrent Cervical Cancer Chemotherapy plus apatinib - Recurrent Cervical Carcinoma, Persistent Advanced Cervical Carcinoma | Phase 2 | Completed | Lei Li | 37 | 2019-12-06 | 2022-03-15 |
| SHR-1210 in Combination With Apatinib in Patients With Metastatic, Persistent, or Recurrent Cervical Cancer SHR-1210, Apatinib - Recurrent Cervical Carcinoma, Metastatic Cervical Cancer | Phase 2 | Completed | Sun Yat-sen University | 45 | 2019-01-19 | 2023-04-11 |
| DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine INO-3112 and Durvalumab in Treating Patients With Recurrent or Metastatic Human Papillomavirus Associated Cancers DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine MEDI0457, Durvalumab - Human Papillomavirus-16 Positive, Human Papillomavirus-18 Positive | Phase 2 | Terminated | M.D. Anderson Cancer Center | 41 | 2018-11-14 | 2024-07-09 |
| Atezolizumab and Bevacizumab in Treating Patients With Recurrent, Persistent, or Metastatic Cervical Cancer Atezolizumab, Bevacizumab, Laboratory Biomarker Analysis - Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma | Phase 2 | Completed | National Cancer Institute (NCI) | 11 | 2017-03-10 | 2023-02-21 |
| Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) Adavosertib, Afatinib, Afatinib Dimaleate - Advanced Lymphoma, Advanced Malignant Solid Neoplasm | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 6452 | 2015-08-17 | 2026-10-26 |
| Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer Laboratory Biomarker Analysis, Nivolumab - Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 26 | 2015-05-18 | 2026-10-22 |
| Ipilimumab in Treating Patients With Metastatic or Recurrent Human Papilloma Virus-Related Cervical Cancer Ipilimumab, Laboratory Biomarker Analysis - Cervical Adenocarcinoma, Cervical Squamous Cell Carcinoma | Phase 2 | Completed | National Cancer Institute (NCI) | 42 | 2012-12-03 | 2022-11-08 |
| Vaccine Therapy in Treating Patients With Persistent or Recurrent Cervical Cancer Attenuated Live Listeria Encoding HPV 16 E7 Vaccine ADXS11-001, Laboratory Biomarker Analysis - Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma | Phase 2 | Completed | Gynecologic Oncology Group | 54 | 2011-05-23 | 2020-09-11 |
| Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer Brivanib Alaninate, Laboratory Biomarker Analysis - Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma | Phase 2 | Completed | Gynecologic Oncology Group | 31 | 2011-04-04 | 2019-03-20 |
| Veliparib, Topotecan Hydrochloride, and Filgrastim or Pegfilgrastim in Treating Patients With Persistent or Recurrent Cervical Cancer Filgrastim, Laboratory Biomarker Analysis, Pegfilgrastim - Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma | Phase 2 | Completed | National Cancer Institute (NCI) | 27 | 2011-02-01 | 2019-08-08 |
| Temsirolimus in Treating Patients With Cervical Cancer That Is Recurrent, Locally Advanced, Metastatic, or Cannot Be Removed By Surgery Temsirolimus, Laboratory Biomarker Analysis - Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma | Phase 2 | Completed | National Cancer Institute (NCI) | 38 | 2009-12-01 | 2015-09-10 |
| Cetuximab in Treating Patients With Persistent or Recurrent Cervical Cancer Cetuximab - Cervical Squamous Cell Carcinoma, Recurrent Cervical Carcinoma | Phase 2 | Completed | Gynecologic Oncology Group | 38 | 2007-06-01 | 2015-01-13 |
Showing 20 of 25. Sign in to see all of them.
Uterine Cervical Neoplasms (25) · Anal Canal Carcinoma (1) · Anus Neoplasms (1) · Breast Neoplasms (1) · Carcinoma, Hepatocellular (1) · Carcinoma, Renal Cell (1) · Colonic Neoplasms (1) · Colorectal Neoplasms (1) · Drug-Related Side Effects and Adverse Reactions (1) · Endometrial Neoplasms (1) · Esophageal Neoplasms (1) · Glioma (1) · Hematologic Neoplasms (1) · Lung Neoplasms (1) · Lymphoma (1)
Female Urogenital Diseases (25) · Female Urogenital Diseases and Pregnancy Complications (25) · Genital Diseases (25) · Genital Diseases, Female (25) · Genital Neoplasms, Female (25) · Neoplasms by Site (25) · Urogenital Diseases (25) · Urogenital Neoplasms (25) · Uterine Cervical Diseases (25) · Uterine Diseases (25) · Neoplasms (24) · Uterine Neoplasms (24) · Digestive System Diseases (2) · Digestive System Neoplasms (2) · Disease Attributes (2)
Albumin-Bound Paclitaxel (3) · Disulfides (3) · Immunoglobulin G (3) · Drug Therapy (2) · Nivolumab (2) · Paclitaxel (2) · Radiotherapy (2) · Taxes (2) · apatinib (2) · 2-(3-(2-(1-isopropyl-3-methyl-1H-1,2-4-triazol-5-yl)-5,6-dihydrobenzo(f)imidazo(1,2-d)(1,4)oxazepin-9-yl)-1H-pyrazol-1-yl)-2-methylpropanamide (1) · 2C4 antibody (1) · AZD4547 (1) · Ado-Trastuzumab Emtansine (1) · Afatinib (1) · Bevacizumab (1)
Gynecologic Oncology Group (7) · Lei Li (7) · National Cancer Institute (NCI) (7) · M.D. Anderson Cancer Center (1) · Meghan Shea (1) · Precigen, Inc (1) · Sun Yat-sen University (1)
United States (16) · China (8) · Canada (2) · Guam (1) · Puerto Rico (1) · Spain (1)
Lei Li, M.D. (7) · Agustin Garcia (1) · Alessandro D Santin (1) · Alessandro Santin (1) · Amit M Oza (1) · Anna Tinker (1) · Charles Kunos (1) · Claire F Friedman (1) · D. McMeekin (1) · David Alberts (1) · Dennis Kuo (1) · John K Chan (1) · Katherine Look (1) · Keith T Flaherty (1) · Meghan Shea, MD (1)
PMID 19931137, PMID 26586415, PMID 28728751, PMID 31924334, PMID 32463741, PMID 32641240, PMID 33004542, PMID 33048619, PMID 33052760, PMID 34011535, PMID 35133871, PMID 35138919, PMID 36115931, PMID 36351402, PMID 37053535, PMID 37322121, PMID 37934000, PMID 38591867, PMID 39666929, PMID 39693587, PMID 39913886, PMID 40865033, PMID 41066729
U10CA027469 (8), U10CA180868 (4), N01CM00032 (1), N01CM00038 (1), N01CM00071 (1), N01CM62204 (1), P30CA013330 (1), U10CA180820 (1), U10CA180821 (1), U10CA180830 (1), U24CA196172 (1), UM1CA186691 (1), UM1CA186705 (1)